Page 2 - Formp News Today

StockNews.com downgraded shares of Oramed Pharmaceuticals (NASDAQ:ORMP – Get Rating) from a hold rating to a sell rating in a report published on Monday morning. A number of other research analysts also recently weighed in on ORMP. Canaccord Genuity Group downgraded Oramed Pharmaceuticals from a buy rating to a hold rating and dropped their price […]

Private Portfolio Partners LLC lowered its holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) by 20.5% during the fourth quarter, Holdings Channel.com reports. The firm owned 53,600 shares of the biotechnology company’s stock after selling 13,800 shares during the period. Private Portfolio Partners LLC’s holdings in Oramed Pharmaceuticals were worth $645,000 at the end […]

Oramed Pharmaceuticals (NASDAQ:ORMP – Get Rating) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday. Several other equities analysts have also recently issued reports on the company. Cantor Fitzgerald cut Oramed Pharmaceuticals from an “overweight” rating to […]

Shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) passed above its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $7.47 and traded as high as $8.29. Oramed Pharmaceuticals shares last traded at $7.96, with a volume of 188,755 shares traded. Analysts Set New Price Targets ORMP […]

Strs Ohio cut its stake in shares of Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) by 41.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,400 shares of the biotechnology company’s stock after selling 3,900 shares during the quarter. […]

Wall Street brokerages expect Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) to report sales of $700,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Oramed Pharmaceuticals’ earnings. Oramed Pharmaceuticals posted sales of $680,000.00 in the same quarter last year, which would indicate a positive year-over-year growth rate of […]

Oramed Pharmaceuticals (NASDAQ:ORMP – Get Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a report issued on Thursday. A number of other research firms have also recently commented on ORMP. Cantor Fitzgerald initiated coverage on Oramed Pharmaceuticals in a research report on Friday, February 18th. They set an “overweight” […]

Presidents company and its cfo, that trial is expected to go, that trial is expected in court later this i year, at the end o the summer, beginning of the fall. now, we dont know if any additional charges will be brought in that case at all, particularly with the release af this deposition in which trump claimsio full personal responsibility formp the compensationon arrangement of another employee who appears to have been paid in a similar manner to the man who is here in handcuffs. we have susp...

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) has earned an average rating of “Buy” from the six ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1 year price target among […]

Equities analysts expect that Oramed Pharmaceuticals Inc. (NASDAQ:ORMP – Get Rating) will report earnings per share of ($0.19) for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Oramed Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.23) and the highest estimate coming in at ($0.15). Oramed Pharmaceuticals posted earnings […]